Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study.
The Lancet. Oncology 2015 Jun 16 (6): 686-94.
Konecny Gottfried E, Finkler Neil, Garcia Agustin A, Lorusso Domenica, Lee Paula S, Rocconi Rodney P, Fong Peter C, Squires Matt, Mishra Kaushal, Upalawanna Allison, Wang Yongyu, Kristeleit Rebec
Biomolecular, biochemical, and radiologic evaluation and safety of chemotherapy with bevacizumab in treatment of patients affected by mCRC.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011 May 29 (15_suppl): e14140.
Rossi L, Veltri E, Colonna M, Zoratto F, Vari S, Mottolese M, Di Seri M, Romiti A, Longo F, Giannarelli D, Tomao